What's new? Log in Free sign up

Relmada Therapeutics (RLMD)

Company Profile

Company profile

Ticker

RLMD

Exchange

Website

www.relmada.com

CEO

Dr. Sergio Traversa M.B.A., Pharm.D.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Alabama Power • Mississippi Power • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris ...

Former names

CAMP NINE, INC.

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

RLMD stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Latest filings (excl ownership)

View all

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

Departure of Directors or Certain Officers

Relmada Therapeutics to discontinue the Reliance II and Relight Phase 3 studies of REL-1017

Regulation FD Disclosure

Quarterly report

7 Nov 24

Notice of effectiveness

Shelf registration

Quarterly report

7 Aug 24

Submission of Matters to a Vote of Security Holders

Quarterly report

8 May 24

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Deep Track Capital, LP

CHARLES J CASAMENTO

SERGIO TRAVERSA

CHARLES J CASAMENTO

Paul Edward Kelly

SERGIO TRAVERSA

Paul Edward Kelly

Financial summary

Financial statements Chart RLMD financial data

Quarter (USD)	Sep 24	Jun 24	Mar 24	Dec 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	1.48 mm	1.48 mm	1.48 mm	1.48 mm	1.48 mm	1.48 mm
Cash burn (monthly)	200.82 k	434.57 k	7.67 mm	7.64 mm	5.55 mm	4.43 mm
Cash used (since last report)	808.17 k	1.75 mm	30.86 mm	30.73 mm	22.34 mm	17.84 mm
Cash remaining	675.62 k	-265.04 k	-29.38 mm	-29.25 mm	-20.86 mm	-16.36 mm
Runway (months of cash)	3.4	-0.6	-3.8	-3.8	-3.8	-3.7

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

RLMD institutional ownership history Ownership history

49.2% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	73	82	-11.0%
Opened positions	7	9	-22.2%
Closed positions	16	19	-15.8%
Increased positions	11	15	-26.7%
Reduced positions	25	31	-19.4%

13F shares	Current	Prev Q	Change
Total value	35.33 bn	36.23 bn	-2.5%
Total shares	14.85 mm	16.03 mm	-7.4%
Total puts	137.80 k	42.80 k	+222.0%
Total calls	228.70 k	85.80 k	+166.6%
Total put/call ratio	0.6	0.5	+20.8%

Largest owners	Shares	Value	Change
Venrock Healthcare Capital Partners II	2.27 mm	$0.00	0.0%
BEN Franklin Resources	1.30 mm	$4.36 bn	+28.6%
Vanguard	1.26 mm	$4.07 bn	0.0%
Acadian Asset Management	1.19 mm	$3.84 mm	-0.6%
Parsons Capital Management	1.00 mm	$3.25 bn	+2.7%
Palo Alto Investors	732.40 k	$2.37 bn	0.0%
Deep Track Capital	674.83 k	$2.19 bn	-45.3%
BlackRock	567.88 k	$1.84 bn	NEW
Millennium Management	561.83 k	$1.82 bn	+773.0%
Vestal Point Capital	490.00 k	$1.59 bn	-59.2%

Largest transactions	Shares	Bought/sold	Change
Vestal Point Capital	490.00 k	-710.00 k	-59.2%
BLK BlackRock	0.00	-573.31 k	EXIT
BlackRock	567.88 k	+567.88 k	NEW
Deep Track Capital	674.83 k	-559.94 k	-45.3%
Millennium Management	561.83 k	+497.47 k	+773.0%
BEN Franklin Resources	1.30 mm	+289.49 k	+28.6%
Tang Capital Management	50.83 k	-187.05 k	-78.6%
Shay Capital	175.55 k	+175.55 k	NEW
Opaleye Management	480.00 k	-120.00 k	-20.0%
Marshall Wace	50.57 k	-106.05 k	-67.7%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

RLMD insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
22 Oct 24	Casamento Charles J	Common Stock	Gift	Dispose G	No	No	0	13,000	0.00	0
11 Sep 24	Sergio Traversa	Common Stock	Buy	Acquire P	No	No	2.99	51,407	153.71 k	384,024
11 Sep 24	Maged Shenouda	Common Stock	Buy	Acquire P	No	No	2.95	24,120	71.15 k	88,335
10 Sep 24	Sergio Traversa	Common Stock	Buy	Acquire P	No	No	2.75	33,014	90.79 k	332,617
10 Sep 24	Maged Shenouda	Common Stock	Buy	Acquire P	No	No	2.73	21,118	57.65 k	64,215
9 Sep 24	Sergio Traversa	Common Stock	Buy	Acquire P	No	No	2.71	55,579	150.62 k	299,603
9 Sep 24	Maged Shenouda	Common Stock	Buy	Acquire P	No	No	2.55	8,194	20.89 k	43,097
9 Sep 24	Casamento Charles J	Common Stock	Buy	Acquire P	No	No	2.56	13,000	33.28 k	13,000
9 Sep 24	Paul Edward Kelly	Common Stock	Buy	Acquire P	No	No	2.59	25,000	64.75 k	212,295

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Relmada Therapeutics Announced That In Light Of The Recent Data Monitoring Committee Evaluation Of The Full Dataset From The Reliance II Phase 3 Study Of Rel-1017 Program, The Company Will Discontinue The Reliance II And Relight Phase 3 Studies

The company will continue to advance the Phase 1 study of REL-P11, an investigational agent for the treatment of metabolic disease, currently in a Phase 1 first-in-human study.

Mizuho Downgrades Relmada Therapeutics to Neutral, Lowers Price Target to $1

Mizuho analyst Uy Ear downgrades Relmada Therapeutics (NASDAQ:RLMD) from Outperform to Neutral and lowers the price target from $23 to $1.

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Relmada Therapeutics Stock Plummets Losing 80% Value - Here's Why

Nasdaq Surges 150 Points; ISM Services PMI Falls In November

Press releases

From Benzinga Pro

Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017

CORAL GABLES, Fla., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", "the Company")), a late-stage biotechnology company addressing diseases of the central nervous system (CNS),

Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance

The DMC did not identify any new safety concerns Relmada to evaluate potential next steps for the REL-1017 program Relmada to continue to focus on the development of REL-P11 for metabolic disease Relmada is well

Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm

NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Relmada Therapeutics, Inc. (NASDAQ:RLMD) breached their

Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease

Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.